NASDAQ · LSTA
Healthcare · Biotechnology
$1.01
Up+$0.08 (+7.92%)
Updated Nov 4, 2026, 12:20 AM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LSTA
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
LSTA closed at $1.01 after 20 trading sessions, down 16.53% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $1.08 | $1.148 | $1.00 | $1.01 | 97.15K |
| Oct 30, 2026 | $0.9901 | $1.0899 | $0.9901 | $1.02 | 60.78K |
| Oct 29, 2026 | $1.04 | $1.12 | $0.99 | $1.01 | 27.85K |
| Oct 28, 2026 | $1.01 | $1.12 | $1.01 | $1.06 | 75.39K |
| Oct 27, 2026 | $1.04 | $1.04 | $1.01 | $1.02 | 40.77K |
| Oct 26, 2026 | $0.98 | $1.06 | $0.9612 | $1.06 | 60.32K |
| Oct 23, 2026 | $1.00 | $1.01 | $0.97 | $0.9959 | 45.56K |
| Oct 22, 2026 | $1.06 | $1.06 | $1.00 | $1.005 | 27.67K |
| Oct 21, 2026 | $1.05 | $1.0699 | $1.01 | $1.05 | 45.57K |
| Oct 20, 2026 | $1.00 | $1.08 | $0.996 | $1.04 | 113.74K |
| Oct 19, 2026 | $1.03 | $1.04 | $0.9604 | $1.00 | 96.29K |
| Oct 16, 2026 | $1.04 | $1.07 | $1.02 | $1.03 | 57.13K |
| Oct 15, 2026 | $1.05 | $1.07 | $1.00 | $1.07 | 23.17K |
| Oct 14, 2026 | $1.00 | $1.07 | $0.996 | $1.02 | 80.26K |
| Oct 13, 2026 | $1.10 | $1.1499 | $0.99 | $1.08 | 146.86K |
| Oct 12, 2026 | $1.04 | $1.06 | $0.98 | $1.05 | 166.67K |
| Oct 9, 2026 | $1.28 | $1.28 | $1.02 | $1.06 | 280.23K |
| Oct 8, 2026 | $1.22 | $1.31 | $1.13 | $1.20 | 704.82K |
| Oct 7, 2026 | $1.22 | $1.22 | $1.16 | $1.17 | 13.58K |
| Oct 6, 2026 | $1.31 | $1.3199 | $1.14 | $1.21 | 124.18K |
The latest Smart Investors Daily articles mentioning LSTA.
Company
Market Activity
Research & News
LSTA research
Company profile and research snapshot.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 15, 2026 | HC Wainwright & Co. | Neutral | — |
| Jan 21, 2026 | Brookline Capital | Hold | — |
| Aug 21, 2025 | HC Wainwright & Co. | Buy | — |
| Jul 15, 2025 | Brookline Capital | Buy | — |
| Dec 11, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 8, 2026
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has been granted a new US patent covering its experimental drug certepetide for the treatment of pancreatic cancer and other solid tumors, the company said. The US Patent and Trademark Office issued the Method of Use patent titled "Methods for...
Yahoo · Oct 8, 2026
LIBERTY CORNER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company, today announced that the United States Patent and Trademark Office (“USPTO”) has granted a new Method of Use patent for certepetide [U.S. Patent No. 12,751,991] for the treatment of pancreatic cancer and other solid tumors, expiring May 2041. The newly issued patent, titled “Methods for Treating Pancreatic Cancer and Other Solid Tu
Yahoo · Oct 5, 2026
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) subsidiary Marea Therapeutics has dosed the first patient in a Phase 2 clinical trial of MAR002, a first-in-class antibody therapy for acromegaly, the company said on Monday. Marea, which is developing medicines for cardioendocrine diseases, is...
Yahoo · Oct 5, 2026
Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care By directly blocking growth hormone signaling at the receptor level, MAR002 has the potential to deliver meaningful biochemical control for a broad population of acromegaly patients SOUTH SAN FRANCISCO, Calif. and L
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LSTA.
